Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia

International Journal of Oncology

Volumn 41, Issue 4, 2012, Pages 1475-1485

  Alferez, Denis G ^a,b   Goodlad, Robert A ^a,e   Odedra, Rajesh ^b   Sini, Patrizia ^b   Crafter, Claire ^b   Ryan, Anderson J ^b,c   Wedge, Stephen R ^b   Wright, Nicholas A ^a,d   Anderson, Elizabeth ^b   Wilkinson, Robert W ^b,f  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f MEDIMMUNE   (United States)

Author keywords

Aurora B kinase inhibitors; Barasertib; Barasertib hQPA; Colorectal cancer; Early disease; Neoplasia

Indexed keywords

AURORA B KINASE; BARASERTIB; HISTONE H3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL CARCINOMA; HISTONE PHOSPHORYLATION; HISTOPATHOLOGY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; AURORA KINASE B; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HISTONES; HUMANS; MICE; PHOSPHORYLATION; QUINAZOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866485767     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1580     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Chee CE and Sinicrope FA: Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 39: 601-613, 2010.
3. Keen N and Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4: 927-936, 2004.
4. Yang KT, Li SK, Chang CC, et al: Aurora-C kinase deficiency causes cytokinesis failure in meiosis I and production of large polyploid oocytes in mice. Mol Biol Cell 21: 2371-2383, 2010.
5. Bischoff JR, Anderson L, Zhu Y, et al: A homologue of Drosophila Aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17: 3052-3065, 1998.
6. Pohl A, Azuma M, Zhang W, et al: Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. Pharmacogenomics J 11: 93-99, 2011.
7. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
8. Ilyas M, Straub J, Tomlinson IP and Bodmer WF: Genetic pathways in colorectal and other cancers. Eur J Cancer 35: 1986-2002, 1999.
9. Senda T, Iizuka-Kogo A, Onouchi T and Shimomura A: Adenomatous polyposis coli (APC) plays multiple roles in the intestinal and colorectal epithelia. Med Mol Morphol 40: 68-81, 2007.
10. Hanson CA and Miller JR: Non-traditional roles for the Adenomatous Polyposis Coli (APC) tumor suppressor protein. Gene 361: 1-12, 2005.
11. Boman BM, Walters R, Fields JZ, et al: Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population. Am J Pathol 165: 1489-1498, 2004.
12. Zhang T, Fields JZ, Opdenaker L, et al: Survivin-induced Aurora-B kinase activation: A mechanism by which APC mutations contribute to increased mitoses during colon cancer development. Am J Pathol 177: 2816-2826, 2010.
13. Wilkinson RW, Odedra R, Heaton SP, et al: AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13: 3682-3688, 2007.
14. Preston S, Leedham S, Oukrif D, et al: The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse. J Pathol 214: 294-301, 2008.
15. Minde DP, Anvarian Z, Rüdiger SG and Maurice MM: Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer? Mol Cancer 10: 101, 2011.
16. Chen LC, Hao CY, Chiu YS, et al: Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res 64: 3694-3700, 2004.
17. Corpet DE and Pierre F: How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 41: 1911-1922, 2005.
18. Mortlock AA, Foote KM, Heron NM, et al: Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 50: 2213-2224, 2007.
19. Cummings J, Hodgkinson C, Odedra R, et al: Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Ther 7: 455-463, 2008.
20. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60: 970-975, 2000.
21. Widrow RJ, Rabinovitch PS, Cho K and Laird CD: Separation of cells at different times within G2 and mitosis by cyclin B1 flow cytometry. Cytometry 27: 250-254, 1997.
22. Alferez D, Ryan A, Goodlad R, Wright N and Wilkinson R: Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced ApcMIN/+ mouse model. Int J Oncol 37: 767-772, 2010.
23. Alferez D, Wilkinson RW, Watkins J, et al: Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. Mol Cancer Ther 7: 590-598, 2008.
24. Goodlad RA, Ryan AJ, Wedge SR, et al: Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis 27: 2133-2139, 2006.
25. Alferez D and Goodlad R: To best measure cell proliferation in samples from the intestine. Cell Prolif 40: 231-240, 2007.
26. Nair JS, Ho AL, Tse AN, et al: Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell 20: 2218-2228, 2009.
27. Ditchfield C, Johnson VL, Tighe A, et al: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161: 267-280, 2003.
28. Ota T, Suto S, Katayama H, et al: Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 62: 5168-5177, 2002.
29. Lens SM, Voest EE and Medema RH: Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10: 825-841, 2010.
30. Oke A, Pearce D, Wilkinson RW, et al: AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 69: 4150-4158, 2009.
31. Aihara A, Tanaka S, Yasen M, et al: The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 52: 63-71, 2010.
32. Nair JS, de Stanchina E and Schwartz GK: The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer Res 15: 2022-2030, 2009.
33. Azzariti A, Bocci G, Porcelli L, et al: Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer 104: 769-780, 2011.
34. Grundy M, Seedhouse C, Russell NH and Pallis M: P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer 11: 254, 2011.
35. Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, et al: Assessment of the in vivo antitumor effects of ENMD-2076, a novel multi-targeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res 16: 2989-2998, 2010.
36. Girdler F, Gascoigne KE, Eyers PA, et al: Validating Aurora B as an anti-cancer drug target. J Cell Sci 119: 3664-3675, 2006.
37. Boivin GP, Washington K, Yang K, et al: Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124: 762-777, 2003.
38. Paulsen JE: Modulation by dietary factors in murine FAP models. Toxicol Lett 112-113: 403-409, 2000.
39. Rhodes JM and Campbell BJ: Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med 8: 10-16, 2002.
40. Alison M: The Cancer Handbook. John Wiley & Sons, Chichester, West Sussex, Hoboken, NJ, 2007.
41. Boss DS, Witteveen PO, van der Sar J, et al: Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 22: 431-437, 2011.